CA-ASM-GLOBAL
9.8.2024 15:01:31 CEST | Business Wire | Press release
ASM Global’s culinary division SAVOR, which provides elevated food experiences for the globe’s most prestigious arenas, stadiums, convention/exhibition centers and performing arts venues, has announced the national winners of the American round of the world’s only competition for young culinary and hospitality talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240809474691/en/
Mixologist Winner Marco Guillen, Four Seasons, Napa Valley, California. (Photo: Business Wire)
Thomas Mendel, chef from Hamel Winery; Jaclyn Bisantz, waitress from Harbor House; and Marco Guillen, mixologist from Four Seasons Napa, were crowned as winners of the U.S. leg of the renowned World Young Chef Young Waiter Young Mixologist (WorldYYY) competition — the only event of its kind.
“This syncs very nicely with the work ASM Global does nationally to develop deep relationships with our local communities and reach out to educate, train and employ culinary talent via scholarship, internship and apprenticeship programs,” said Shaun Beard, SAVOR’s senior vice present of food and beverage.
“As ASM Global continues to elevate the food experience in many of the world’s premiere venues, these up-and-coming talents will be part of our universe,” Beard said. “The composure, creativity and determination we’ve seen from all the competitors in this high-pressure situation was truly unmatched and is proof that we have so much to look forward to from these young stars. We are proud to help pave the way for them and are excited to see what they do next.”
SAVOR’s Team USA members will next compete in the WorldYYY finals at Swissôtel The Stamford in Singapore this November. They will showcase their abilities to world-class chefs, hospitality experts and esteemed mixologists. A total of 36 contestants from 12 countries will compete for the world titles of Best Young Chef, Young Waiter and Young Mixologist.
The finals of YYY USA recently took place at the prestigious The Culinary Institute of America at Copia (CIA) in Napa, California, with a panel of expert judges, including Master Chef Roland Passot, propriétaire and chief culinary officer; Tournament of Champions’ Tracey Shepos Cenami, executive chef and cheese specialist at Kendall-Jackson Wine Estate and Gardens; and Food Network Chef Adam Sobel, partner of Mina Group anointing the winners.
ASM Global’s SAVOR division became a strategic partner of the competition nearly five years ago as part of its worldwide commitment to nurturing and identifying new talent, introducing them to the hospitality space and showcasing them to renowned culinary industry leaders.
About SAVOR
SAVOR is the culinary division of ASM Global, the world’s No. 1 development and full-service venue company with a portfolio of more than 400 of the world’s most prestigious arenas, stadiums, convention/exhibition centers and performing arts venues network spanning five continents. The team at SAVOR provides elevated and curated guest experiences at every event, from the food preparation to the beverage offerings, whether for intimate VIP experiences or banquets with over 20,000 guests. In addition to authentic, chef-driven food, the core elements of SAVOR's food vision include partnerships with local growers, producers and community members; a commitment to using antibiotic-free meats and poultry; and dedication to minimizing impact on the environment through robust sustainability, recycling and composting programs. For more information, please visit savorasmglobal.com.
About YYY
Since its establishment in 1979, the Young Chef Young Waiter competition has continued to promote hospitality as a career of choice, a profession and a vocation. Today, with its new revitalized format, Young Chef Young Waiter continues to honor the next culinary and service stars globally. World Young Chef Young Waiter Young Mixologist’s, in partnership with Great Campaign U.K. and Northern Ireland and The Culinary Institute of America, mission is to discover the best young talents in the industry. The competition is open to young chefs, waiters and mixologists age 28 and under from diverse backgrounds. YYY ensures these young talents are equipped with relevant skills, current knowledge and a network to help them succeed in the world of hospitality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240809474691/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom